Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis
Syed Huzaifa Khan, MBBS at Nowshera Medical College, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Clinical Cardiology, adding:
“Glad to share our recent publication.
‘Methodological Considerations in Evaluating CTRP12 as a Biomarker for In-Stent Restenosis’.
The paper highlights important considerations including potential selection/verification bias, lack of multivariable adjustment, and the possibility that early post-PCI CTRP12 levels may reflect acute vascular injury and inflammatory activation rather than processes specifically associated with subsequent restenosis.
The authors also discuss the need for appropriate adjustment of clinical and procedural factors and external validation before CTRP12 can be interpreted as an independent biomarker for in-stent restenosis.”
Title: Methodological Considerations in Evaluating CTRP12 as a Biomarker for In‐Stent Restenosis
Authors: Saleha Khattak, Syed Muhammad Rayyan, Syed Huzaifa Khan
Stay updated with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:29Mirvat Alasnag: Creating a Space for Women in Cardiovascular Medicine